Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for the treatment of solid tumors. The company utilizes two distinct platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs to induce systemic anti-tumor immune responses through in-situ immunization. Its lead product candidate, aglatimagene besadenovec (formerly CAN-2409), is an adenoviral gene therapy administered intratumorally in conjunction with the prodrug valacyclovir, currently in phase 3 trials for localized prostate cancer. A second candidate, linoserpaturev (CAN-3110), is a replication-competent HSV oncolytic virus designed for high-grade glioma. The company serves patients with solid tumors, including prostate, lung, and brain cancers, and has received FDA Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for aglatimagene.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage candeltx.com
Sector Healthcare IR page ir.candeltx.com
Tags
viral immunotherapy, oncolytic viruses, gene therapy, prostate cancer, glioma, solid tumors, adenovirus, herpes simplex virus, intratumoral injection, clinical-stage, aglatimagene besadenovec, CAN-2409, linoserpaturev, CAN-3110, valacyclovir
Press page —

Metrics

Valuation  
Market cap $ 818.976M
Market cap (USD) $ 818.976M
P/E -7.01
PEG —
P/BV 6.22
P/S —
P/OCF -11.89
P/FCF -11.67
Dividend yield —
Turnover / mcap —
Returns  
ROE -64.6%
ROI -38.5%
ROIC -36.5%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 90.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 62
Quality score -78.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue — — — 125K 125K 0
Net profit -38.182M -55.177M -37.939M -18.794M -36.124M 0
Free cash flow -38.898M -27.039M -34.701M -32.716M -24.053M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 5.65 8.68 1.47 1.79 7.82 —
Price performance 12m -0.35 4.9 -0.18 -0.77 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — — — 8.89M 9.9M 0.00
Borrowings, non-current (USD) — — — — 11.6M 1.73M —
Lease liabilities (USD) — — — 1.95M 1.49M 973,000 1.9M
Cash and deposits (USD) 5.45M 35.1M 82.6M 70.1M 35.4M 103M 120M
Right-of-use assets (USD) — — — 1.06M 816,000 542,000 1.66M
Net debt (borrowings + leases - cash) (USD) — — — — -13.4M -90.1M -118M
Cash flow detail
Operating cash flow (USD) — -9.07M -22.2M -31.4M -34.2M -27M -38.3M
Purchases of property, plant and equipment (USD) — -1.48M -1.84M -1.3M -457,000 -16,000 -587,000
Change in payables (cash effect) (USD) — 289,000 669,000 -1.21M 45,000 -185,000 802,000
Interest paid (cash effect) (USD) — — — -1.15M -2.15M -1.8M -1.28M
Income taxes paid (cash effect) (USD) — -93,000 -29,000 -183,000 — — —
Share-based compensation (USD) — 2.11M 2.96M 2.31M 3.09M 5.31M 3.82M
Free cash flow (OCF - PPE - intangibles) (USD) — -10.5M -24.1M -32.7M -34.7M -27M -38.9M
Income detail
Research and development expense (USD) — 8.75M 15.2M 20.8M 24.5M 19.3M 30.5M
↳ 5y CAGR +28.4%
Total comprehensive income (USD) — -17.7M -36.1M — — — —
Comprehensive income to owners (USD) — -17.7M -36.1M — — — —
Reported Sep 8, 2021 Mar 29, 2022 Mar 29, 2022 Mar 30, 2023 Mar 28, 2024 Mar 13, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Candel Therapeutics, Inc. — Other Events Bull 0 Bear 4 Financing

On November 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Open Market Sale AgreementSM (the “2026 Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), from time to time through Jefferies acting as sales agent, having an aggregate offering price of up to $50,000,000 (such amount to be in addition to the aggregate gross sales proceeds received by the Company from the sale of Common Stock prior to the date hereof pursuant to the 2025 Sale Agreement (as defined below)) (the “ATM Shares”). The 2026 Sales Agreement amends and restates that certain Amended and Restated Open Market Sale AgreementSM, dated as of August 14, 2025 (the “2025 Sales Agreement”), between the Company and Jefferies, which had a maximum aggregate offering price of up to $50,000,000. As of November 12, 2026, the Company had sold an aggregate of approximately $50,000,000 of ATM Shares under the 2025 Sales Agreement.

On November 12, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Oct 29, 2026

PDF Version

NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking abstract from its phase 2 PrTK05 clinical trial evaluating aglatimagene besadenovec (aglatimagene) in localized prostate cancer has been accepted for poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.

The presentation will feature longitudinal immune-profiling findings from PrTK05 (NCT07332000), together with biodistribution and viral shedding data, providing additional insights into the biological activity and characterization of aglatimagene in patients with localized intermediate-risk prostate cancer.

The poster presentation details are as follows:

Title: Longitudinal immune profiling in the PrTK05 trial of aglatimagene besadenovec plus valacyclovir with radiation therapy for localized intermediate-risk prostate cancer

Presenter: Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics

Abstract Number: 1172

Session Date: Saturday, November 7, 2026

Location: Phoenix Convention Center - North Building - Lower Level - Exhibition Halls 4, 5 and 6

About aglatimagene besadenovec

Aglatimagene besadenovec (aglatimagene), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) with results published in the Journal for ImmunoTherapy of Cancer, and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any use.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform and is currently in an ongoing phase 3 clinical trial in NSCLC. Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

Prompts

Candel Therapeutics, Inc. (ticker CADL), listed in United States.

ETFs Holding Candel Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
CANC 0.53% 86,337 $ 1.128M Aug 31, 2026
VFMO 0.07% 97,719 $ 1.277M Aug 31, 2026
RESM 0.02% 68 $ 700.40 Jun 30, 2026
MSSM 0.01% 5,299 $ 69.258K Aug 31, 2026